DNLI vs GH: fair value comparison
Denali Therapeutics Inc. and Guardant Health, Inc. · Updated 2026-10-19
DNLI has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. GH has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DNLI currently ranks higher by quality score.
| DNLI | GH | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $17.61 | $158.60 |
| 12-month range | $14.41–$27.21 | $69.35–$187.22 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #99 of 301 Healthcare | #101 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Stable | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: DNLI fair value analysis · GH fair value analysis